About Us
About Us
Our team
We are the integrated team of high professionals with expertise covering all aspects of managing and execution of international and local clinical trials, non-interventional and real world data studies. Our management team prior individual working experience in Big Pharma is up to 20 years.
Our previous long-term work in international pharmaceutical companies has given us valuable knowledge and practical skills, which we are constantly improving.
Moreover, our associates possess prior clinical and academic experience in clinical pharmacology, cardiology, respiratory diseases, emergency medicine, endocrinology, neurology, rheumatology, immunology, oncology and pediatrics.
We are committed to investing in the development and support of our personnel. We believe that our people are our strength.
Our previous long-term work in international pharmaceutical companies has given us valuable knowledge and practical skills, which we are constantly improving.
Moreover, our associates possess prior clinical and academic experience in clinical pharmacology, cardiology, respiratory diseases, emergency medicine, endocrinology, neurology, rheumatology, immunology, oncology and pediatrics.
We are committed to investing in the development and support of our personnel. We believe that our people are our strength.
Mission
To meet patients’ needs and improve their quality of life by investing our knowledge and experience into new pharmaceutical products development through providing cost-effective and high quality services to pharmaceutical companies.
Facts about ALMEDIS
ALMEDIS has been a member of the Association of Clinical Trial Organizations (ACTO) since 2008 participating actively in its work.
In 2021 ALMEDIS marks the fifteen years of successful collaboration with a leading international Life Sciences technology provider Ennov.
In Russia ALMEDIS was the first SAS local subscriber for clinical trials (see SAS web-page for more information). Using SAS since 2009, ALMEDIS has been successfully conducting studies for many customers, including projects for half of the Top-10 international pharmaceutical companies operating in Russia.
Since 2007 ALMEDIS has been an official subscriber of MedDRA - an international dictionary of standardized medical terminology which we work with in the field of data management and pharmacovigilance.
In 2018-2019, ALMEDIS participated in the translation of MedDRA into Russian, contributing to the implementation of standard coding processes in the practice of pharmacovigilance and clinical trials in Russia.
In 2021 ALMEDIS marks the fifteen years of successful collaboration with a leading international Life Sciences technology provider Ennov.
In Russia ALMEDIS was the first SAS local subscriber for clinical trials (see SAS web-page for more information). Using SAS since 2009, ALMEDIS has been successfully conducting studies for many customers, including projects for half of the Top-10 international pharmaceutical companies operating in Russia.
Since 2007 ALMEDIS has been an official subscriber of MedDRA - an international dictionary of standardized medical terminology which we work with in the field of data management and pharmacovigilance.
In 2018-2019, ALMEDIS participated in the translation of MedDRA into Russian, contributing to the implementation of standard coding processes in the practice of pharmacovigilance and clinical trials in Russia.